Fund mangers have fallen in love with TechnologyOne, but after a surge in its share price, now it must deliver.

High wages aren’t the real productivity problem. It's the outdated and overly complex award system that's holding back growth ...

Australia now has a statutory tort of privacy — but with broad exemptions for journalists, the media is unlikely to ever be ...

Fresh from receiving FDA approval, the $1.3 billion medical device company is one of the stronger performers on the ASX this year. But short sellers sniff weakness.